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tients. The study employed a cross-sectional design. Eighty-nine female university students
with primary dysmenorrhea were included in the study. All patients underwent complete clin-
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were used to evaluate associations between continuous data. Categorical associations were
evaluated using c2 test. Correlation analysis between serum ADMA and AMH levels in the study
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p Z 0.01). Our study has shown a significant positive correlation between serum ADMA and
AMH levels in primary dysmenorrhea. Serum ADMA levels may have the potential to demon-
strate ovarian reserve.
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Asymmetric dimethylarginine (ADMA) is an important
marker in a variety of clinical settings, playing a role in
endothelial dysfunction. It is associated with the patho-
genesis of atherosclerosis, hypertension, and diabetic
vascular complication, as well as primary dysmenorrhea
(PD), polycystic ovary syndrome, and pregnancy-related
disorders such as preeclampsia and hyperemesis grav-
idarum [1e3]. Changes in serum ADMA levels have also been
investigated during normal menstrual periods. The men-
strual cycle is divided into follicular and luteal phases and is
regulated by hormones [4]. Estrogen and progesterone
levels are lower in the early period of the follicular phase,
but start to increase toward the end of the follicular phase,
peaking during the surge of luteinizing hormone and
follicle-stimulating hormone. In the early period of luteal
phase and during the follicular phase, progesterone levels
are very low, but start to increase in advancing of luteal
phase [4]. Serum ADMA levels undergo small changes during
the menstrual cycle. Levels are higher in the follicular
phase of the cycle than in the luteal phase. These findings
are well-correlated with flow-mediated dilatation, which
indicates that endothelial dysfunction is highest in the
follicular phase. Furthermore, oral contraceptive therapy
reduces changes in serum ADMA levels in the normal men-
strual cycle. Also, serum ADMA levels are significantly
decreased by oral contraceptives in women with polycystic
ovary syndrome. Orally administered hormone replacement
therapy also has an effect on circulating ADMA levels [5].
Estrogen-containing pills decrease serum ADMA concentra-
tions, whereas progestin-only pills do not, as compared
with controls. Estrogen has a positive effect on endothelial
functions, inducing arterial vasodilation by activating
endothelial nitric oxide synthase. Estradiol may facilitate
nitric oxide synthesis by reducing circulating levels of
ADMA, which may then exert protective effects on the
vasculature [6e8].
AMH is specifically produced by late preantral and small
antral follicles. AMH controls folliculogenesis by restricting
primordial follicle development, inhibiting the sensitivity of
larger antral follicles to follicle-stimulating hormone and
aromatase during ovulatory cycles. Serum AMH levels are
generally accepted as a marker for prediction of the ovarian
reserve. Women in the youngest age group, 18e30 years,
show the highest levels of AMH, but then experience an age-
related decrease associated with ovarian reserve and levels
of the ovarian follicular pool [9e14]. AMH is also amarker for
prediction of in vitro fertilization success rates in terms of
ovarian response to ovarian stimulation [15e17].
Factors such as ethnicity, body mass index (BMI), smok-
ing, and physical activity affect serum AMH levels as well as
serum ADMA levels [9].
The definite pathogenesis of PD remains unclear, but
studies have shown that prostaglandins and vasoactive
mediators are increased in the endometrium and menstrual
specimens [18]. Recent studies have also shown that some
hormonal or vascular endothelial functional changes, such
as increased vasopressin and serum ADMA levels, cause
vasoconstriction, uterine contractions, and eventually
uterine ischemia related to the menstrual pain in PD. PDalso affects other systems and may lead to an increase in
the risk of cardiac arrhythmia or mental status change
during the menstrual period [4,18].
Serum AMH levels change during the menstrual cycle as
well as serum ADMA levels, but peak concentrations of
serum AMH occur in the late follicular phase w4e5 days
before ovulation. In general, variations in serum AMH levels
occur during the follicular and luteal phases. Serum AMH
levels are used to detect the ovarian follicular pool and
ovarian reserve in women. This is a useful technique for the
prediction of quantitative and qualitative aspects and
success estimation in assisted reproductive technologies
[15]. Besides the common factors effecting ADMA/AMH and
estrogen related common pathway mentioned above, our
main hypothesis is the possible presence of a close rela-
tionship between serum AMH and ADMA levels in PD pa-
tients. A more potent ovarian reserve may lead to more
prominent serum ADMA elevation. Thus, the objective of
our study was to investigate the association of serum ADMA
and AMH levels in PD patients.
Materials and methods
Study group
This is a substudy of a previous scientific project evaluating
the pathophysiology and clinical aspects of primary
dysmenorrhea in young women. The study cohort was
selected among the faculty medical student population
from January 2015 to October 2015. Eighty-nine female
university students with primary dysmenorrhea were
included in this study. The investigation conforms to the
principles outlined in the Declaration of Helsinki and the
Ethical Committee approved the study. Informed consent
was obtained, and clinical and demographic data were
collected from each participant.
Patients
A detailed medical history was taken. Each participant
underwent a complete gynecologic examination, including
pelvic ultrasound; systemic physical examination, including
the cardiac and cardiovascular systems; and laboratory
tests such as biochemistry tests, electrocardiography, and
echocardiography. Participants with any gynecological dis-
ease, rheumatic disorder, inflammatory bowel disease, fi-
bromyalgia, known malignancy, known premature coronary
artery disease, congenital cardiac disease, such as family
history of premature coronary artery disease, diabetes
mellitus, hypertension, any endocrine disease such as dia-
betes mellitus or thyroid disorders, endometriosis, ovarian
cysts, and participants taking any oral contraceptive drugs
were excluded. The participants’ main complaint was
dysmenorrhea. Pain was mostly located in lower abdominal
and pelvic area. Pain intensity measured by the Visual
Analog Scale (VAS) was significantly correlated with scores
measured by verbal and numeric scales. The VAS is a tool
commonly used in research and clinical practice, and its
reliability and validity in pain assessment have been clearly
demonstrated [19]. The VAS score is derived from a 10-cm
scale, with end points of 0 for “no pain” and 10 for “worst
Table 2 ADMA and AMH levels according to VAS
categories.
VAS category n Serum ADMA,
mgyL
mean (SD)
Serum AMH,
ngymL
mean (SD)
1e4 (Mild) 24 35.2 (24) 2.9 (1.2)
5e7 (Moderate) 39 54.0 (28.7) 6.2 (0.8)
416 N. Akdemir et al.pain”. The use of the scale was clearly explained to all
participants. Patients were asked to make a mark on the
line representing their pain intensity. The distance from the
“no pain” end to the patient’s mark was used to represent
pain intensity level [19]. Grading from 1e4 was accepted as
mild; 5e7 was accepted as moderate; and 8e10 was
accepted as severe pain. The associations of ADMA and AMH
levels in different pain groups were analyzed.
Laboratory analyses
Blood samples were taken from each participant in the
morning after 12 hours fasting on the 3rd day of menses.
After clotting and centrifugation for 5 minutes at 3.00 g,
serum for AMH and ADMA measurement was separated and
stored at 80C until the time of analysis. Blood glucose,
serum creatinine, blood urea nitrogen, lactate dehydroge-
nase, alkaline phosphatase, aspartate and alanine amino-
transferases, gamma glutamyl trans peptidase, and
bilirubin were measured via an ARCHITECT c16000 auto
analyzer (Abbott Laboratories, Abbott Park, Illinois, USA).
ADMA and AMH levels were measured using commercial
enzyme-linked immunosorbent assay kits (Shanghai Yehua
Biological Technology, Shanghai, China) according to the
manufacturer’s instructions. Intra-assay variability co-
efficients of ADMA and AMH ELISA assays were 9.2% and
10.6%, respectively. ADMA and AMH levels were expressed
as micrograms per liter (mg/L) and nanogram per milliliter
(ng/mL) in serum samples, respectively.
Statistics
Data were analyzed via statistical software SPSS, version
10.0 [SPSS Inc, Chicago, IL, USA]. The distribution charac-
teristics of continuous data were determined usingTable 1 Clinical, demographic, laboratory characteristics
of patients with primary dysmenorrhea (n Z 89).
Characteristics Mean (SD), %
Age 21.08  2.21
BMI (kg/m2) 22.4  1.9
Smoking 8 (8.9)
Alcohol 5 (5.6)
Physical activity intensity Lowemoderate:
65 (73), Intense:
26 (27)
Age at menarche (y) 13.2  1.3
Pain duration (day) 1  0.76
Visual analogue scale (VAS) pain scores 5.9101  2.18
Asymmetric dimethylarginine (ADMA) 49.6594  29.63
Anti-Mu¨llerian hormone (AMH) 9.8762  5.50
(VAS) Pain category
Frequency (%)
VAS Cat 1e4 24 (26.8)
VAS Cat 5e7 39 (43.8)
VAS Cat 8e10 26 (29.2)
BMI Z body mass index; Cat Z category; SD Z standard
deviation.histogram examination and the one-sample Kolmogor-
oveSmirnov test. Normally distributed data were presented
as mean (standard deviation) and compared with one-way
analysis of variance (ANOVA). Further analyses were per-
formed using Tukey’s honestly significant difference test as
needed. Pearson’s correlation and linear regression analysis
were used to evaluate associations among continuous data.
Categorical associations were evaluated via a c2 test. Data
binning was applied in the case of embryo number. This
process is a data preprocessing technique used to reduce
the effects of minor observation errors. The statistical
program placed the results into harmonic groups with
optimal binning thresholds. Statistical significance was
defined as p  0.05.
Results
There were 89 women with primary dysmenorrhea in the
study. Mean (standard deviation; SD) age was 21 (2.2). Mean
(SD) BMI was 22.4 (1.9). Other demographic and clinical
data, as well as serum ADMA and AMH levels of the study
group, are presented in Table 1. After patients were
grouped according to VAS categories, serum ADMA and AMH
levels were compared between groups. ANOVA univariate
analysis revealed there was significant difference in ADMA
levels between groups (p Z 0.008). Further analysis was8e10 (Severe) 26 56.5 (32.8) 8.4 (0.7)
ADMA Z asymmetric dimethylarginine; AMH Z anti-Mu¨llerian
hormone; VAS Z visual analogue scale.
Figure 1. ADMA levels according to VAS groups.
ADMAZasymmetricdimethylarginine;VASZvisualanaloguescale.
Serum ADMA and AMH levels in dysmenorrhea 417performed using Tukey’s test, showing that the VAS 5e7 and
VAS 8e10 groups had significantly higher serum ADMA levels
compared with VAS 1e4 group (p Z 0.018 and 0.012,
respectively), whereas there were no significant differ-
ences in mean serum ADMA levels between VAS 5e7 and VAS
8e10 groups (p Z 0.845). Similarly, there was a significant
difference in serum AMH between VAS groups (p Z 0.010).
Further analysis via Tukey’s test revealed that serum AMH
levels were significantly higher in VAS 5e7 and VAS 8e10
groups compared with VAS 1e4 group (pZ 0.015 and 0.024,
respectively), whereas there were no significantFigure 2. AMH levels in different VAS groups. AMH Z anti-
Mu¨llerian hormone; VAS Z visual analogue scale.
Figure 3. Scatterplot depicting correlation between serum ADMA
Mu¨llerian hormone.differences in mean serum ADMA levels between the VAS
5e7 and VAS 8e10 groups (p Z 0.984) (Table 2, Figures 1
and 2). Correlation analysis between serum ADMA and
AMH levels in the whole study group showed a significant
positive relationship (Pearson correlation Z 0.978,
p Z 0.01) (Figure 3). Thus, we proceeded with linear
regression analysis. The regression model included only
serum ADMA and AMH. It revealed that ADMA was a signif-
icant independent predictor of serum AMH (Table 3). As-
sumptions of linear regression were met and adjusted R2
was 95.6%.Discussion
This study has demonstrated a highly significant positive
correlation between serum ADMA and AMH levels in the PD
patient group. We graded dysmenorrhea pain as mild,
moderate, or severe and evaluated the association of serum
ADMA and AMH levels. In comparisons among pain groups,
serum ADMA and AMH levels significantly differed between
the severe and mild pain intensity groups. However, there
was no significant difference between moderate to severe
pain groups in serum ADMA and AMH levels. Thus, we also
found that more severe pain was associated with higher
serum ADMA and AMH levels. This study has demonstrated
the association of serum ADMA and AMH levels for the first
time in the literature.
In a normal menstrual period, changes in serum ADMA
and AMH levels, although minimal, are similar due to
menstrual physiology. This may explain the highly signifi-
cant positive correlation between serum ADMA and AMH
levels in our study [10e16].and AMH. ADMAZ asymmetric dimethylarginine; AMHZ anti-
Table 3 Linear regression analysis of AMH where ADMA is
the independent predictor.
Model B Standard Error Beta t p
Constant 0.858 0.255 d 3.37 0.001
ADMA 0.182 0.004 0.978 41.181 <0.001
ADMA Z asymmetric dimethylarginine; AMH Z anti-Mu¨llerian
hormone; B Z unstandardized coefficient; t Z statistic.
418 N. Akdemir et al.In a mouse model, increased serum ADMA levels were
found to be positively correlated with bone morphogenic
protein receptor-2 gene mutation. This was also seen in the
pathogenesis of a primary pulmonary hypertension study,
which concluded that changes in bone morphogenetic
protein signaling and enzymes involved in arginine
methylation may contribute to explaining the pathophysi-
ological significance of elevated ADMA levels [20].
Three AMH receptors have been described in studies into
the genetic relations of AMH. These Type I receptors, ALK2,
ALK3, and ALK 6, are shared with bone morphogenetic
proteins (BMPs). Subsequently, similar to BMPs, AMH
signaling is mediated through the downstream signaling
molecules Smad1, Smad5, and Smad8. However, the rela-
tive contributions of these three Type I receptors to AMH
signaling in the ovary remain undetermined [20e23].
As we discussed above, both ADMA and AMH use similar
signal pathways and the same signaling system. Therefore,
increased serum ADMA levels may trigger the excess syn-
thesis of AMH or vice versa. Serum ADMA levels may be said
to show ovarian reserve as well as serum AMH levels,
whereas serum AMH levels may be used to evaluate
vascular endothelial function [20e22].
Gene expressions in endothelial cells are triggered by
very small changes in the concentration of ADMA. The
identification of pathways regulated by ADMA may aid our
understanding of how ADMA contributes to a wide range of
pathologies. Two pathways of specific interest have been
identified: BMP signaling and enzymes involved in arginine
methylation. The effects on BMP signaling may be partic-
ularly important in renal disease, as well as in the link
between raised ADMA and pulmonary hypertension. Serum
AMH levels may also be increased in those diseases, as in
our study of the PD patient group [20]. Finally, it should be
noted that there are conflicting data in the literature
regarding chronic pelvic pain and serum AMH levels. For
example, contrary to our study, severe menstrual pain was
associated with lower AMH among Japanese women aged 20
to 22 years. This may be explained by inclusion of a high
percentage of patients with endometriosis in that study,
whereas endometriosis causes chronic pelvic pain similar to
PD, AMH levels have been shown to be lower [10].Limitations
Those results may not represent the population at large, as
our study group was chosen from among PD patients. The
absence of a control group, absence of follow-up data,
single blood sampling, and small sample size are limitations
of this study. Further studies incorporating genetic andbiochemical research are needed to clarify the association
of serum ADMA and AMH levels in an unselected population.
There is a significant positive correlation between serum
ADMA and AMH levels in PD. These results may be explained
by two factors: (1) both share similar changes during the
cycle; and (2) they share similar genetic signaling path-
ways. Serum ADMA levels have the potential to be used to
evaluate ovarian reserve.
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